Data / Form D filings / Immunis, Inc.
Immunis, Inc.: Form D filings
Immunis, Inc., a biotechnology company in Irvine, CA, filed 3 Form D notices with the SEC between 2024 and 2026. The latest, on June 15, 2026, reports $12 million sold of a $12 million offering to 12 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 18301 Von Karman Avenue Suite 350, Irvine, CA, 92612
- Phone
- (949) 266-2501
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2028798
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | New notice | $11,975,000 | $11,975,000 | 12 | May 28, 2026 | sec.gov | |
| Oct 24, 2024 | Amendment | $25,000,000 | $20,389,963 | $4,610,037 | 27 | Jun 17, 2024 | sec.gov |
| Jul 1, 2024 | New notice | $20,000,000 | $15,793,916 | $4,206,084 | 18 | Jun 17, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Hans Keirstead | Executive Officer, Director | |
| Takahide Koda | Director | |
| Daniel Kraft | Director | |
| Gabriel Nistor | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jun 15, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Immunis, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.